Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response

Leukemia & Lymphoma
Kota FukumotoKosei Matsue

Abstract

To investigate the impact of immunophenotypic complete response [iCR, ≤10(-4) multiple myeloma (MM) cells defined by multicolor flow cytometry (MFC)] on survival in patients with MM, we retrospectively analyzed 78 patients that obtained conventional CR at our hospital. Survivals were landmarked at achievement of CR. The rate of stringent CR (sCR) among patients with CR was 88%, and iCR for CR and sCR patients were 44% and 49%, respectively. Achievement of iCR was associated with significantly longer disease-free survival (DFS) not only in CR patients (p = 0.009) but also in sCR patients (p = 0.002), while sCR attainment per se did not have statistically significant impact on DFS (p = 0.06) or overall survival (OS) (p = 0.587). Univariate and multivariate analyses indicated that attainment of iCR was independently associated with longer 2-year DFS in addition to creatinine (≤2.0 mg/dL) and maintenance therapy. This study highlights the importance of pursuing iCR even in patients with sCR.

References

May 10, 2003·Blood·Paolo CorradiniUNKNOWN Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Jul 20, 2004·British Journal of Haematology·G P MeadA R Bradwell
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Feb 13, 2008·Haematologica·Andy C RawstronUNKNOWN European Myeloma Network
Aug 2, 2008·Blood·Bruno PaivaUNKNOWN GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Grou
Feb 5, 2011·Blood·Nikhil C MunshiUNKNOWN International Myeloma Workshop Consensus Panel 2
Mar 16, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruno PaivaJesus F San Miguel
Dec 1, 2011·Blood·Bruno PaivaUNKNOWN PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study G
May 4, 2012·Leukemia·J J M van DongenUNKNOWN EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708)
May 11, 2012·The New England Journal of Medicine·Michel AttalUNKNOWN IFM Investigators
Jun 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andy C RawstronRoger G Owen
Oct 29, 2013·Blood Cancer Journal·H CaillonH Avet-Loiseau
Nov 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Prashant KapoorMorie A Gertz
Jan 28, 2015·Nature Reviews. Clinical Oncology·Sham MailankodyOla Landgren
Jun 20, 2015·Blood·Joaquín Martínez-LópezUNKNOWN Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative

❮ Previous
Next ❯

Citations

Oct 21, 2017·Blood Cancer Journal·T JelinekR Hajek
Feb 9, 2020·International Journal of Hematology·Hiroyuki Takamatsu
Jan 1, 2020·Expert Review of Precision Medicine and Drug Development·Matthew HoKenneth C Anderson

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
P KapoorM A Gertz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Bruno PaivaJesus F San Miguel
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Zhengjun YangXuchen Cao
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
L W van BockelC H J Terhaard
© 2022 Meta ULC. All rights reserved